Fosolin (Fosphenytoin Vials) 75mg/2ml

Fosolin (Fosphenytoin) 75mg/2ml vials offer anticonvulsant therapy for seizure control. This injectable formulation provides broad-spectrum seizure management in clinical settings. Fosolin is indicated for patients requiring intravenous or intramuscular antiepileptic treatment. Store between 2-8°C to maintain potency.

Strength

75mg/2ml

Pack Size

10s

Storage

2-8°

Manufacturer / TM Owner

Zydus Cadila

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fosolin (Fosphenytoin) is used to treat generalized tonic-clonic seizures and status epilepticus. It serves as an alternative when oral phenytoin therapy is impractical. Fosolin provides rapid seizure control in emergency and hospital settings. The 75mg/2ml strength allows flexible dosing for adult and pediatric patients requiring injectable anticonvulsant therapy.

Side Effects

Fosolin may cause dizziness, headache, or injection site reactions during administration. Some patients report mild nausea or drowsiness after treatment. These effects typically resolve as the medication clears the system. Individual responses vary based on medical history and concurrent medications.

Precautions & Warnings

Fosolin requires careful administration by healthcare professionals in controlled environments. Monitor patients for signs of allergic reactions or cardiovascular effects during infusion. Store vials refrigerated at 2-8°C and protect from light. Discard any unused portion after opening to maintain sterility.

Avoid Interactions

Fosolin may interact with medications that affect liver enzymes, including certain antidepressants and anticoagulants. Alcohol consumption should be avoided during treatment due to increased sedation risk. Inform healthcare providers about all current medications before Fosolin administration. CYP450 inducers may alter Fosolin metabolism.

Frequently Asked Questions

Fosolin is used to treat seizures, including generalized tonic-clonic seizures and status epilepticus.

Fosolin vials should be refrigerated between 2-8°C and protected from light.

Fosolin requires administration by healthcare professionals in clinical settings.

Common effects include dizziness, headache, and injection site reactions.

Fosolin is a prodrug that converts to phenytoin in the body for anticonvulsant activity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.